The MRM1 Knockout AGS Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population targeting the MRM1 gene within the AGS human gastric adenocarcinoma cell line. This knockout model is generated through CRISPR/Cas9-mediated gene disruption, resulting in a mixed population of cells with diverse loss-of-function alleles, thereby providing a robust system for studying the consequences of MRM1 deficiency without clonal biases. The polyclonal format avoids artifacts associated with single-cell cloning and is well-suited for pooled functional genomics approaches.
The host cell line, AGS, is derived from a patient with gastric adenocarcinoma and exhibits adherent epithelial morphology. As a widely employed model in gastric cancer research, AGS cells retain key features of gastric tumor biology, including dysregulated signaling pathways and metabolic rewiring. This background provides a clinically relevant platform to interrogate the role of mitochondrial gene expression in the context of gastric cancer pathogenesis.
MRM1 (mitochondrial rRNA methyltransferase 1) catalyzes 2′-O-methylation at position U1369 of the mitochondrial 12S rRNA, a modification essential for the proper folding and assembly of the mitoribosome. This enzymatic function places MRM1 as a critical node in mitochondrial gene expression, with its activity regulated by upstream factors such as PGC-1??, NRF1, and TFAM, which coordinate mitochondrial biogenesis. Downstream, MRM1-mediated modification influences the maturation of the small mitochondrial ribosomal subunit, directly impacting the translation of mitochondrial-encoded proteins including COX1 and ND1. MRM1 likely interacts with mitochondrial ribosomal proteins and assembly factors, and possible crosstalk with other rRNA methyltransferases like NSUN4 may fine-tune ribosomal function. Disruption of MRM1 leads to defective mitochondrial translation, diminished oxidative phosphorylation capacity, and altered cellular energetics.
In the AGS gastric cancer model, MRM1 knockout perturbs mitochondrial respiration and ATP production, forcing metabolic adaptation that can influence tumor cell proliferation, survival, and sensitivity to metabolic stress. Given the reliance of gastric cancer cells on oxidative phosphorylation and metabolic plasticity, this knockout model serves as a powerful tool to dissect the interplay between mitochondrial function and oncogenic signaling. The AGS background allows direct assessment of how MRM1 loss impacts hallmarks of cancer, such as metabolic reprogramming and growth in nutrient-poor microenvironments.
Researchers can employ this polyclonal knockout population in a variety of functional assays, including Seahorse-based mitochondrial stress tests, Western blotting for OXPHOS subunits, RT-qPCR analysis of mitochondrial transcripts, and RiboMethSeq to assess rRNA modification status. Additionally, metabolic phenotyping via ATP measurements and lactate production assays, as well as cell proliferation studies, can elucidate the role of MRM1 in cancer metabolism. This knockout model is valuable for drug target validation in gastric cancer and mitochondrial disorders, and for mechanistic studies of mitochondrial gene expression. For further information or to discuss customized applications, please contact Ascent Research.
